Please login to the form below

Not currently logged in
Email:
Password:

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

Keytruda

Merck & Co has added yet another new indication to the tally for its PD-1 checkpoint inhibitor Keytruda, picking up an FDA green light for use of the drug in stomach cancer.

The US regulator has cleared the drug as a third-line option after chemotherapy for patients with recurrent locally-advanced or metastatic gastric or gastroesophageal junction cancer, whose tumours express the biomarker PD-L1.

The verdict adds to a bumper crop of new approvals for Keytruda (pembrolizumab) in the last few months, during which it's won okays for first-line non-small cell lung cancer (NSCLC) in combination with chemo, second-line bladder cancer and microsatellite instability-high (MSI-H) cancer, the first time that a drug has been approved to treat all cancers with a specific tumour biomarker.

The company notes that Keytruda is the first PD-1 inhibitor to be approved for stomach cancer in the US and will be used for patients who have disease progression despite two or more prior lines of chemo or - in some cases - HER2-targeted therapy.

It’s now picked up 10 indications in its first three years on the market, and the new use in gastric cancer will add to its breakneck sales momentum, with revenues from the drug rising to almost $1.5bn in the first six months of the year.

Keytruda has been approved based on the results of the KEYNOTE-059 study in 259 patients, 143 of whom were PD-L1 expressers above the threshold for entry into the trial. Among these, Keytruda achieved an overall response rate of just over 13% (19 patients), with a complete response rate of 1.4%. Around half the responders lived for six months and longer, with a quarter surviving beyond 12 months.

The expected survival of patients with metastatic gastric cancer is less than one year with very few new drugs approved for this disease in the past decade, and there is currently no standard of care for treatment third-line and beyond.

Bristol-Myers Squibb’s rival PD-1 inhibitor Opdivo (nivolumab) has also shown activity in this setting in an Asian study and was approved in Japan for this indication last week. Opdivo has also just picked up a US approval as a second-line treatment for hepatocellular carcinoma - a common form of liver cancer - in patients previously treated with Bayer’s Nexavar (sorafenib).

Article by
Phil Taylor

26th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics